pharmaphorum5h
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
GEN19h
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
The Pharma Letter6h
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
STAT16m
Patrizia Cavazzoni, former head of FDA’s drug center, joins Pfizer as chief medical officer
Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.
National Audubon Society19h
Your Guide to the Audubon Bird Guide App
The Audubon Bird Guide is a free and complete field guide to over 800 species of North American birds, right in your pocket. Built for all experience levels, it will help you identify the birds around ...